A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS.
How J, et al.
EJHaem. 2022 Mar 6;3(2):434-442. doi: 10.1002/jha2.408. eCollection 2022 May.
EJHaem. 2022.
PMID: 35846042
Free PMC article.